Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0953 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.0953 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0953 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0953 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0953 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0953 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0953 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.0953 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0953 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0953 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0953 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0953 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0953 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.065 | 0.1468 | 0.1468 |
Onchocerca volvulus | 0.0953 | 1 | 1 | |
Plasmodium falciparum | hexokinase | 0.0953 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0953 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0953 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0953 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.0953 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0953 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0953 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0953 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.0953 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0953 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.0953 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0953 | 1 | 0.5 |
Onchocerca volvulus | 0.0953 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.0953 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0953 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.